Cytokinetics
CYTK----
Cytokinetics (CYTK)
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors a...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Cytokinetics Analyst Rating
View MoreForecast & Rating
Jul 22, 2026Price forecast
$107.8031.59%
Forecast & RatingBuy
22analysts
- Strong buy59.09%
- Buy31.82%
- Hold9.09%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · 1 hour ago
Cytokinetics EVP R&D Malik Fady Ibraham disposes of 3,500 common shares for $282,065
- Unusual Whales · 2 hours ago
Cytokinetics to Announce Second Quarter Results on August 6, 2026
- PUBT · 2 hours ago
Cytokinetics schedules Q2 earnings release, conference call
- StockTitan · Jul 17 at 07:00 AM
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CYTK Stock News
- Simplywall · Jul 15 at 08:08 AM
Cytokinetics (CYTK) Could Be 22% Undervalued On Its Growth Narrative
- PUBT · Jul 14 at 02:35 PM
Cytokinetics CEO Robert I. Blum disposes of 7,500 common shares for $615,150
